Viatris agrees to buy Pacira BioSciences for $36.50 a share in cash, valuing deal at $1.65 billion
VTRS•Viatris agreed to buy Pacira BioSciences for $36.50 per share in cash, valuing the equity at about $1.65 billion. Viatris expects to fund the deal mainly with excess cash and target closing by the end of 2026.
1. Deal terms
Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, valuing its equity at about $1.65 billion. Viatris expects to fund the deal mainly with excess cash and use short-term borrowings for the remainder. Closing is targeted by the end of 2026; Pacira would become a wholly owned Viatris unit and be delisted from Nasdaq.
2. Pacira business
Pacira brings EXPAREL and ZILRETTA, two marketed, patent-protected non-opioid pain therapies in the U.S. It generated about $746 million in revenue and $177 million in adjusted EBITDA in the 12 months ended June 30, 2026.
